Innovative CAR T-cell therapy shows promising results in pre-clinical testing for myeloproliferative neoplasms

EHA/ICML 2025

Lymphoma

Expanding the Curative Potential of CAR T-Cell Therapy

Further Publications

A Bright Future for Immunotherapy: CAR T-Cell Therapy Promises Revolutionary Changes

healthbook TIMES Onco Hema

Rybachuk VA, Evstratova ES, Klabukov ID, Ivanov SA, Shegai PV, Kaprin AD, Baranovsky DS

doi: 10.36000/HBT.OH.2024.22.164

Further Publications

Chimeric Antigen Receptor T-Cells (CAR T-Cells) in Hematological Malignancies: A Systematic Review and Meta-Analysis of Proportions From Clinical Trials

Am J Hematol

Filippatos C, Kanteli I, Pasipoularidou DG, Gavriatopoulou M, Tentolouris A, Malandrakis P, Sergentanis TN, Terpos E, Ntanasis-Stathopoulos I

doi: 10.1002/ajh.70201

Lymphoma

Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell Therapy

Blood

Kaulen LD, Martinez-Lage M, Abramson JS, Karschnia P, Doubrovinskaia S, Shankar GM, Choi BD, Ramundo CM, Ehret F, Barnes JA, El-Jawahri A, Hochberg E, Johnson PC, Soumerai JD, Plotkin SR, Batchelor TT, Wick W, Maus MV, Chen YB, Frigault MJ, Dietrich J

doi: 10.1182/blood.2025028964

Multiple Myeloma (MM)

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium

Blood Cancer J

Varga C, Robinson M, Davis JA, Hashmi H, Martin TG, Kumar A, Sborov DW, Wagner CB, Hansen DK, Castaneda Puglianini O, Shune L, Bhurtel E, Afrough A, Anderson LD Jr, Dhakal B, Herr MM, Richard S, Lieberman-Cribbin A, Sherbenou D, Forsberg PA, Purvey S, Khouri J, Lin Y, Sidana S, Patel KK, Kocoglu M, Midha S, Ferreri CJ

doi: 10.1038/s41408-026-01469-z

ASH 2025

Lymphoma

Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL

ASH 2025

Multiple Myeloma (MM)

LBA-1: Early MRD negativity following the novel in vivo CAR T-cell therapy KLN-1010 in patients with RRMM

Lymphoma

CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis

Am J Hematol

Gauthier J, Ahn KW, Patel J, Lian Q, Badawy S, Cairo MS, Delgado J, Grover N, Haverkos B, de Lima M, Malone A, Mussetti A, Nieto Y, Pawarode A, Pearson L, Solh M, Sureda A, Tun AM, Wudhikarn K, Yamshon S, Shadman M, Turtle CJ, Hamadani M, Herrera AF

doi: 10.1002/ajh.70033

Lung, Respiratory and Thoracic Cancer

CAR-T cell therapy for the treatment of lung cancer: Current challenges and emerging therapeutic strategies

Lung Cancer

Shi D, Yan X, Liu J, Chen H, Wang X, Li R, Tian X, Lin X, Wang Y

doi: 10.1016/j.lungcan.2025.108849

Related content

Expanding the Curative Potential of CAR T-Cell Therapy

A Bright Future for Immunotherapy: CAR T-Cell Therapy Promises Revolutionary Changes

Chimeric Antigen Receptor T-Cells (CAR T-Cells) in Hematological Malignancies: A Systematic Review and Meta-Analysis of Proportions From Clinical Trials

Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell Therapy

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium

Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL

LBA-1: Early MRD negativity following the novel in vivo CAR T-cell therapy KLN-1010 in patients with RRMM

CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis

CAR-T cell therapy for the treatment of lung cancer: Current challenges and emerging therapeutic strategies